These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29054474)

  • 21. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15.
    Azzi S; Bruno S; Giron-Michel J; Clay D; Devocelle A; Croce M; Ferrini S; Chouaib S; Vazquez A; Charpentier B; Camussi G; Azzarone B; Eid P
    J Natl Cancer Inst; 2011 Dec; 103(24):1884-98. PubMed ID: 22043039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Layers of DUB regulation.
    Sahtoe DD; Sixma TK
    Trends Biochem Sci; 2015 Aug; 40(8):456-67. PubMed ID: 26073511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
    Kuo KK; Lee KT; Chen KK; Yang YH; Lin YC; Tsai MH; Wuputra K; Lee YL; Ku CC; Miyoshi H; Nakamura Y; Saito S; Wu CC; Chai CY; Eckner R; Steve Lin CL; Wang SS; Wu DC; Lin CS; Yokoyama KK
    Stem Cells; 2016 Nov; 34(11):2613-2624. PubMed ID: 27341307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer stem cell targeted agents: therapeutic approaches and consequences.
    Chumsri S; Burger AM
    Curr Opin Mol Ther; 2008 Aug; 10(4):323-33. PubMed ID: 18683096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of cancer stem cells in developing therapeutic resistance in oral cancer.
    Naik PP; Das DN; Panda PK; Mukhopadhyay S; Sinha N; Praharaj PP; Agarwal R; Bhutia SK
    Oral Oncol; 2016 Nov; 62():122-135. PubMed ID: 27865365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming.
    Suresh B; Lee J; Kim KS; Ramakrishna S
    Stem Cells Int; 2016; 2016():6705927. PubMed ID: 26880980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An alginate-based platform for cancer stem cell research.
    Qiao SP; Zhao YF; Li CF; Yin YB; Meng QY; Lin FH; Liu Y; Hou XL; Guo K; Chen XB; Tian WM
    Acta Biomater; 2016 Jun; 37():83-92. PubMed ID: 27109764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of ubiquitin modifying enzymes in neoplastic disease.
    Kumari N; Jaynes PW; Saei A; Iyengar PV; Richard JLC; Eichhorn PJA
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):456-483. PubMed ID: 28923280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of cancer stem cells in the treatment of cancer.
    Pan CX; Zhu W; Cheng L
    Future Oncol; 2006 Dec; 2(6):723-31. PubMed ID: 17155899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
    Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
    Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells.
    Huang J; Chen T; Liu X; Jiang J; Li J; Li D; Liu XS; Li W; Kang J; Pei G
    Cell Res; 2009 Oct; 19(10):1127-38. PubMed ID: 19736564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention.
    Gasch C; Ffrench B; O'Leary JJ; Gallagher MF
    Mol Cancer; 2017 Feb; 16(1):43. PubMed ID: 28228161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).
    Kharkar PS
    Expert Opin Ther Pat; 2017 Jul; 27(7):753-761. PubMed ID: 28460551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer stem cells: the development of new cancer therapeutics.
    Scatena R; Bottoni P; Pontoglio A; Giardina B
    Expert Opin Biol Ther; 2011 Jul; 11(7):875-92. PubMed ID: 21463158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status in cancer cell reprogramming and its clinical implications.
    Izgi K; Canatan H; Iskender B
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deubiquitinating Enzyme-Mediated Signaling Networks in Cancer Stem Cells.
    Kaushal K; Ramakrishna S
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells.
    Hao J; Zhang Y; Deng M; Ye R; Zhao S; Wang Y; Li J; Zhao Z
    Int J Cancer; 2014 Sep; 135(5):1019-27. PubMed ID: 24500893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice?
    Sánchez-García I; Vicente-Dueñas C; Cobaleda C
    Bioessays; 2007 Dec; 29(12):1269-80. PubMed ID: 18022789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.